-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Image: Kaplan-Meier DFS
Oncotarget published "Targeting NGS-identified TP53 mutations in breast cancer: a case-control study", the study reported that the purpose of our research was to evaluate the potential of TP53 somatic mutations detected by next-generation sequencing as breast cancer patients.
The role of prognostic markers
.
23 cases of somatic cell TP53 mutations and 23 healthy controls matched in age at diagnosis, menopausal status, histological subtype, histological grade, ki67 expression and disease stage
.
The coexistence of PIK3CA mutations is a common finding in somatic tp53 mutant tumors
In univariate Cox regression analysis, TP53 pathogenic somatic mutations were associated with an 8-fold risk of recurrence
.
This case-control study shows that the somatic mutation of TP53 detected by next-generation sequencing is associated with the poor prognosis of breast cancer
Dr.
Flora Zagouri from Alexandra Hospital School of Medicine said: "TP53 gene is the most commonly mutated gene (>50%) in human cancer, indicating its important role as a tumor suppressor
.
"
The TP53 gene encodes the p53 protein, which is considered to be the "guardian of the genome", which binds to a specific DNA sequence to maintain the stability of the genome
.
P53 protein participates in the cell's response to stress signals, activates DNA repair proteins and regulates the production of stem cells
There are many studies evaluating the clinical significance of TP53 mutations in breast cancer
.
However, the results of these studies are often contradictory
The Zagouri research team concluded in their Oncotarget Research Output, “We show here that TP53 pathogenic somatic mutations are associated with shorter DFS in patients with early breast cancer
.
In addition, TP53 mutations often coexist with PIK3CA mutations in breast tumors ( 17.
